Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Miniaturized iPS-Cell-Derived Cardiac Muscles for Physiologically Relevant Drug Response Analyses

Open access
Huebsch, Nathaniel, Loskill, Peter, Deveshwar, Nikhil, Spencer, C. Ian, Judge, Luke M., Mandegar, Mohammad A., B. Fox, Cade, Mohamed, Tamer M.A., Ma, Zhen, Mathur, Anurag, Sheehan, Alice M., Truong, Annie, Saxton, Mike, Yoo, Jennie, Srivastava, Deepak, Desai, Tejal A., So, Po-Lin, Healy, Kevin E., Conklin, Bruce R.·2016·Scientific Reports

Abstract

Tissue engineering approaches have the potential to increase the physiologic relevance of human iPS-derived cells, such as cardiomyocytes (iPS-CM). However, forming Engineered Heart Muscle (EHM) typically requires >1 million cells per tissue. Existing miniaturization strategies involve complex approaches not amenable to mass production, limiting the ability to use EHM for iPS-based disease modeling and drug screening. Micro-scale cardiospheres are easily produced, but do not facilitate assembly of elongated muscle or direct force measurements. Here we describe an approach that combines features of EHM and cardiospheres: Micro-Heart Muscle (μHM) arrays, in which elongated muscle fibers are formed in an easily fabricated template, with as few as 2,000 iPS-CM per individual tissue. Within μHM, iPS-CM exhibit uniaxial contractility and alignment, robust sarcomere assembly and reduced variability and hypersensitivity in drug responsiveness, compared to monolayers with the same cellular composition. μHM mounted onto standard force measurement apparatus exhibited a robust Frank-Starling response to external stretch and a dose-dependent inotropic response to the β-adrenergic agonist isoproterenol. Based on the ease of fabrication, the potential for mass production and the small number of cells required to form μHM, this system provides a potentially powerful tool to study cardiomyocyte maturation, disease and cardiotoxicology in vitro.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep24726

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 29

  1. Mathur, A. et al. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem cell research & therapy. 4 Suppl 1, S14 (2013). · DOI
  2. Bian, W. et al. N. Robust T-tubulation and maturation of cardiomyocytes using tissue-engineered epicardial mimetics. Biomaterials. 35(12), 3819–28 (2014). · DOI
  3. Nunes, S. S. et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 10(8), 781–7 (2013). · DOI · Paper page
  4. Mathur, A. et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci. Rep. 5, 8883 (2015). · DOI · Paper page
  5. Tiburcy, M. et al. Terminal differentiation, advanced organotypic maturation and modeling of hypertrophic growth in engineered heart tissue. Circ Res. 109, 1105–1114 (2011). · DOI
  6. Zimmermann, W. H. et al. Tissue engineering of a differentiated cardiac muscle construct. Circ Res. 90(2), 223–30 (2002). · DOI · Paper page
  7. Thavandiran, N. et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc. Natl. Acad. Sci. USA 110(49), E4698–707 (2013). · DOI · Paper page
  8. Miyaoka, Y. et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods. 11(3), 291–3 (2014). · DOI · Paper page
  9. Vollert, I. et al. In Vitro Perfusion of Engineered Heart Tissue Through Endothelialized Channels. Tissue Eng. Part A. 20(3–4), 854–63 (2014).
  10. Legant, W. R. et al. Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues. Proc. Natl. Acad. Sci. USA 106(25), 10097–102 (2009). · DOI · Paper page
  11. Boudou, T. et al. A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues. Tissue Eng. Part A. 18(9–10), 910–9 (2012). · DOI · Paper page
  12. Feinberg, A. W. et al. Functional differences in engineered myocardium from embryonic stem cell-derived versus neonatal cardiomyocytes. Stem Cell Reports. 1(5), 387–96 (2013). · DOI
  13. Ribeiro, A. J. et al. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physyiological shape and substrate stiffness. Proc. Natl. Acad. Sci. USA 112(41), 12705–10 (2015). · DOI · Paper page
  14. Tiburcy, M. & Zimmermann, W. H. Modeling myocardial growth and hypertrophy in engineered heart muscle. Trends Cardiovasc Med. 24(1), 7–13 (2014). · DOI
  15. Desroches, B. R. et al. Functional scaffold-free-3-D cardiac microtissues: a novel model for the investigation of heart cells. Am J Physiol Heart Circ Physiol. 302, H2031–42 (2012). · DOI
  16. Toyhama, S. et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 12(1), 127–37 (2013). · DOI · Paper page
  17. Hockemeyer, D. et al. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell. 3(3), 346–53 (2008). · DOI · Paper page
  18. Zhang, D. et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials. 34, 5813–20 (2013). · DOI · Paper page
  19. Huebsch, N., Loskill, P. et al. Automated video-based analysis of contractility and calcium flux in human-induced pluripotent stem-derived cardiomyocytes cultured over different spatial scales. Tissue Eng. Part C. Methods. 21(5), 467–79 (2015). · DOI · Paper page
  20. Camelliti, P., Borg, T. K. & Kohl, P. Structural and functional characterization of cardiac fibroblasts. Cardiovasc Res. 65(1), 40–51 (2005). · DOI · Paper page
  21. Nguyen, D. C. et al. Microscale generation of cardiospheres promotes robust enrichment of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Reports. 3(2), 260–8 (2014). · DOI
  22. Oyer, J. A. et al. Aberrant Epigentic Silencing Is Triggered by a Transient Reduction in Gene Expression. PLos One. 4(3), e4832 (2009). · DOI
  23. Navarrete, E. G. et al. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation. 129(15), e452 (2013).
  24. Gorder-Furnémont, A. F. et al. Physiologic force-frequency response in engineered heart muscle by electromechanical stimulation. Biomaterials. 60, 82–91 (2015). · DOI
  25. Yang, X. et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 72, 296–304 (2014). · DOI · Paper page
  26. Ribeiro, M. C. et al. Functional maturation of human pluripotent stem cell derived cardiomyocytes in vitro–corelation between contraction force and electrophysiology. Biomaterials. 51, 138–50 (2015). · DOI · Paper page
  27. Ruan, J. L. et al. Mechanical Stress Promotes Maturation of Human Myocardium from Pluripotent Stem Cell-Derived Progenitors. Stem Cells. 33(7), 2148–57 (2015). · DOI
  28. Kirkton, R. D. & Bursac, N. Engineering biosynthetic excitable tissues from unexcitable cells for electrophysiological and cell therapy studies. Nat. Commun. 2, 300 (2011). · DOI
  29. Schaefer, J. A. & Tranquillo, R. T. Tissue Contraction Force Microscopy for Optimization of Engineered Cardiac Tissue. Tissue Eng Part C Methods. 22(1), 76–83 (2016). · DOI

Cited by

See all 229

Metadata

Authors
Huebsch, N., Loskill, P., Deveshwar, N., Spencer, C. I., Judge, L. M., Mandegar, M. A., B. Fox, C., Mohamed, T. M. A., Ma, Z., Mathur, A., Sheehan, A. M., Truong, A., Saxton, M., Yoo, J., Srivastava, D., Desai, T. A., So, P.-L., Healy, K. E., & Conklin, B. R.
Venue
Scientific Reports
Published
2016-04-20
Volume
6
Issue
1
Pages
24726-24726
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2338837420
Cited by
229
References
10
FWCI
14.14
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.